These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 1518435

  • 1. Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide.
    Chanson P, Warnet A.
    Metabolism; 1992 Sep; 41(9 Suppl 2):62-5. PubMed ID: 1518435
    [Abstract] [Full Text] [Related]

  • 2. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
    Chanson P, Weintraub BD, Harris AG.
    Ann Intern Med; 1993 Aug 01; 119(3):236-40. PubMed ID: 8323093
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
    Colao A, Merola B, Ferone D, Marzullo P, Cerbone G, Longobardi S, Di Somma C, Lombardi G.
    Eur J Endocrinol; 1995 Aug 01; 133(2):189-94. PubMed ID: 7655643
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY, Weissberger AJ, Marbach P, Lazarus L.
    Ann Intern Med; 1990 Feb 01; 112(3):173-81. PubMed ID: 2404445
    [Abstract] [Full Text] [Related]

  • 6. Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Lee EJ, Kim KR, Lim SK, Lee HC, Kim DI, Kim SH, Huh KB.
    Eur J Endocrinol; 1994 Jul 01; 131(1):109-12. PubMed ID: 8038902
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
    Shimatsu A, Murabe H, Kamoi K, Suzuki Y, Nakao K.
    Endocr J; 1999 Feb 01; 46(1):113-23. PubMed ID: 10426575
    [Abstract] [Full Text] [Related]

  • 10. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
    de Bruin TW, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW, Croughs RJ.
    J Clin Endocrinol Metab; 1992 Nov 01; 75(5):1310-7. PubMed ID: 1430093
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).
    Warnet A, Lajeunie E, Gelbert F, Duet M, Chanson P, Cophignon J, Harris AG.
    Acta Endocrinol (Copenh); 1991 Apr 01; 124(4):487-91. PubMed ID: 2031445
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
    Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J.
    J Clin Endocrinol Metab; 1992 Aug 01; 75(2):540-6. PubMed ID: 1353505
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.